Published

Psychedelics and substance use disorder treatment.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: International review of neurobiology
Date: 2025-01-01
Source: PubMed
DOI: 10.1016/bs.irn.2025.03.005
PubMed: 40541314

Authors

DuPont CM Johnson MW

Watch author

Derived topics and classifications

psilocybin Addiction Emotional Processing Clinical Trial Observational Study Safety Clinical Trial

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

Psilocybin Decreases Preference for Large Rewards Accompanied by Increased Activity of Parvalbumin Neurons With Perineuronal Nets in the Medial Prefrontal Cortex2026-06-01

Related papers

Computationally, Electrophysiologically, and Qualitatively Characterizing Serotonergic Psychedelics; Transdiagnostic Therapeutic and Pro-Psychotic EffectsClinicalTrials.gov · 2026-07-09 Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder: A Double-Blind, Dose-Comparison Concurrent Control Randomized TrialClinicalTrials.gov · 2026-08-13 PsiloStudy: A Phase 2 Single-site, Double-blind, Placebo-controlled, Randomized Clinical Trial With an Open-label Extension Phase to Examine the Safety, Subjective Experiences, Acute Effects, and Suitability of Psilocybin Combined With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring Alcohol Use Disorder (AUD) and Posttraumatic Stress Disorder (PTSD)ClinicalTrials.gov · 2026-08-13 Phase I Study of the Safety and Adjunctive Effects of Psilocybin in Adults With Opioid Use Disorder Maintained on a Buprenorphine/Naloxone FormulationClinicalTrials.gov · 2026-07-07 Safety and Feasibility of Psilocybin in Methamphetamine Use Disorder in a Community-Based SampleClinicalTrials.gov · 2026-05-12 Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use DisorderClinicalTrials.gov · 2026-03-30 Safety, Feasibility, and Tolerability of Psilocybin Treatment for Individuals With Functional Impairment Related to Mood, Anxiety, Trauma and/or Addiction Symptoms: An Open-label Proof-of-concept StudyClinicalTrials.gov · 2026-03-11 Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder: A Pilot Randomized Clinical TrialClinicalTrials.gov · 2026-02-12